In this article
Eli Lilly
on Thursday launched a new program designed to help more employers cover obesity drugs in the U.S., targeting a major barrier to access for patients.
Lilly and its chief rival, Novo Nordisk
, have moved to slash the cash prices of their popular obesity injections for those who want to pay entirely out-of-pocket. But employer coverage of obesity drugs remains uneven due to high costs, leaving roughly half of people with commercial insurance unable to start or stay on treatment, Lilly said in a release. List prices for Lilly’s weight loss and diabetes treatments, Zepbound and Mounjaro, top $1,000 per month.
